Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

TCR2 Therapeutics

Main focus: Next-generation iPSC-derived cell therapies

Company stage: Clinical

Diseases (gene editing): Solid tumours, haematological cancers

Genome editing tool: CRISPR

Funding stage: Public (NASDAQ:TCRR)

Location: Cambridge, MA, USA



Gene editing partnerships: Arbor Biotechnologies

TCR2 Therapeutics is developing next-generation cellular therapies to treat cancer. The company's technology is based on TCR Fusion Construct (TRuC) T cells that are engineered to recognise tumour cells. The company's engagement in the gene-editing space comes through its collaboration with Arbor Biotechnologies, giving TCR2 access to CRISPR-based gene-editing systems for the development of allogeneic cell therapies.


HashtagTCR2 Therapeutics

Company: TCR2 Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine